MET and non-small cell lung carcinoma: In the clinical setting 5-20% of NSCLC patients with acquired resistance to EGFR-TKIs have MET-amplification likely due to clonal selection by TKI-treatment of preexisting MET-amplified cells, resulting in activated MET-signaling, which bypasses EGFR-blockade and induces cell proliferation and survival [3, 4, 33].